Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 1/20 | 0.60 |
| ▸ | GUSB | P08236 | 14/20 | 0.54 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25722414 | 0.82 | HPSE (0.64) | HPSEGUSBAMY1ANPC1RAB9A | |
| SCHEMBL7512341 | 0.82 | RHEB (0.63) | NPC1RAB9A | |
| SCHEMBL20982796 | 0.81 | MEN1 (0.57) | HPSENPC1RAB9A | |
| SCHEMBL6325549 | 0.80 | ALDH1A1 (0.68) | HPSEGUSBNPC1RAB9A | |
| SCHEMBL7393557 | 0.80 | GUSB (0.79) | HPSEGUSBAMY1A | |
| SCHEMBL24075313 | 0.80 | HPSE (0.61) | HPSEGUSBNPC1RAB9A | |
| SCHEMBL3333916 | 0.80 | GUSB (0.79) | HPSEGUSBAMY1ANPC1RAB9A | |
| SCHEMBL3337332 | 0.79 | METAP2 (0.62) | HPSEGUSBNPC1RAB9A | |
| SCHEMBL28179657 | 0.79 | HPSE (0.60) | HPSEGUSBAMY1A | |
| Hydrochloric Acid SCHEMBL10736606 | 0.78 | GUSB (0.77) | HPSEGUSBAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | HPSE 2784/4885GUSB 2205/4885AMY1A 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.